We are bringing the cutting edge of therapeutic antibody science to companion animal health.
Whilst therapeutic monoclonal antibodies as we know them have been around for the last 35 years, the use of antibodies in medicine goes back more than 130 years. In 1890 Behring and Kitasato found that antibodies could be used to protect against toxins from diphtheria and tetanus. However, this relied on preparations from human or animal serum donors and the side effects were often as bad as the disease itself. This is because it is very important to give an antibody that is pure and right for the species of the patient.
The progress of therapeutic antibodies
When monoclonal antibodies were first approved by the FDA, they were from mice and so were what is known as ‘immunogenic’ – the patient’s immune system recognised them as foreign and this reduced efficacy of the treatment and often made the patient sick. Over time, antibody drugs have had less and less mouse sequence in them and that has improved how they work. Today the gold standard in human medicine is fully human antibodies produced by mice that have had their antibody genes replaced with human ones. These antibodies are made using a healthy mouse immune system, with all of its benefits for drug quality and efficacy, and are a 100% match for the patient.
PetMedix is taking this approach and using sophisticated chromosome engineering techniques to develop breakthrough therapies that work. Our Ky9™ and Felyne™ platforms can be used to generate therapeutic-quality antibodies immediately and without further need for complex protein engineering steps that often lead to low quality drugs at great expense. Our innovations make for faster, cheaper, and more successful drug discovery and are how we will rapidly develop the therapies our pets need and deserve.